Clinton Seeks $220 Million for Poor Women

Oncology NEWS InternationalOncology NEWS International Vol 9 No 4
Volume 9
Issue 4

WASHINGTON-President Clinton has proposed spending $220 million over 5 years to pay for the treatment of women diagnosed in the federally supported National Breast and Cervical Cancer Early Detection Program.

WASHINGTON—President Clinton has proposed spending $220 million over 5 years to pay for the treatment of women diagnosed in the federally supported National Breast and Cervical Cancer Early Detection Program.

Mr. Clinton included the money in his proposed budget for fiscal year 2001 and urged Congress to enact the legislation necessary to create a new Medicaid option that would enable states to provide low-income, uninsured women with treatment for breast and cervical cancer.

The early breast and cervical cancer detection program now covers 360,000 women nationwide. However, once a diagnosis is made, there is no formal program to ensure a woman will receive prompt, comprehensive treatment, although federally sponsored screening programs try to obtain some therapy for such patients.

“Too often, uninsured women face a patchwork of care, inadequate care, or no care at all,” Mr. Clinton said in one of his weekly radio addresses, in which he announced the initiative. “Many are denied new or better forms of treatment, or wait months to see a doctor.”

According to a White House statement, “women who are uninsured are 40% more likely to die from breast cancer than those with insurance.” Finding treatment for these women diverts scarce resources from screening activities.

The proposed new Medicaid option would enable states, if they choose, to:

Provide the full Medicaid benefit package to low-income, uninsured women diagnosed with breast and cervical cancer through the federal detection program.

Ensure access to treatment without delay. “States would also have the option to allow health care providers and other qualified entities to provide critical health care services to women pending official enrollment in Medicaid,” the White House statement said.

Increase the amount actually spent on breast and cervical cancer screening. Some states currently supplement the federal funds they receive with state money for the treatment of the two diseases.

Related Videos
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
The randomized, placebo-controlled, double-blind phase 3 CALLA trial assessed the combination of durvalumab and chemoradiotherapy vs placebo and chemoradiotherapy.
Findings from the phase 3 CALLA trial indicated that intensity modulated radiation therapy was administered in 88.1% of patients with high-risk locally advanced cervical cancer treated with durvalumab and chemoradiotherapy vs 88.1% with placebo and chemoradiotherapy.
Jyoti S. Mayadev, MD, indicated that durvalumab (Imfinzi) plus chemotherapy resulted in low rates of high-grade late-onset toxicities in the phase 3 CALLA trial, which may be due in part to the quality of the technology employed during the study.
Jyoti S. Mayadev, MD, indicated that future research for cervical cancer will be focused on combination immune checkpoint inhibitors and biomarker research.
Durvalumab appeared to have no impact on the ability to deliver safe and timely radiation therapy to patients with high-risk locally advanced cervical cancer, according to Jyoti S. Mayadev, MD.
The 12-month progression-free survival rates among patients with high-risk locally advanced cervical cancer were comparable with durvalumab plus chemoradiotherapy vs placebo plus radiotherapy.
Cervical Cancer
woman speaking with physician
Related Content